By getting out of unprofitable product lines, Teva showed the way for industry to stabilize pricing and value in the US retail generics sector, the Israeli group’s president and CEO Kåre Schultz told investors at a J.P. Morgan conference.
More stable operating conditions in the US retail generics market are due in large part to actions taken by Teva Pharmaceutical Industries to prune its product portfolio, the Israeli group’s president and CEO, Kåre Schultz, has told investors.
Responding to a question on the firm’s US generics business during a breakout session at the J.P. Morgan Healthcare Conference...
Video provides a powerful way to help you prove your point. When you click Online Video, you can paste in the embed code for the video you want to add. You can also type a keyword to search online for the video that best fits your document.
Polpharma has struck a deal with MSN Laboratories that will see the Polish generics player distribute the Indian firm’s hospital portfolio in Poland.
Following the FDA’s approval of A 150mg version of Accord’ Herceptin biosimilar, the US agency has now greenlit a higher 400mg strength version of the rival.
During Hikma’s first-half results call, the company delved into details of its strategic goals for biosimilars, small-molecule generics, injectables, GLP-1s and more.
Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.
Emerging CRISPR innovations, shifting regulatory landscapes, and rising partnerships are accelerating a paradigm shift in biotech pipelines
After US President Joe Biden launched a review of the country’s API supply chain, the task force has reported back with key vulnerabilities that contribute to drug shortages and supply risks during a global public health emergency. According to the report, the lack of geographic diversity and dependence on foreign nations and anti-competitive actions by foreign nations are key areas of concern.
